Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

Tolvaptan in patients with autosomal dominant polycystic kidney disease.

Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang J, Czerwiec FS; TEMPO 3:4 Trial Investigators.

N Engl J Med. 2012 Dec 20;367(25):2407-18. doi: 10.1056/NEJMoa1205511. Epub 2012 Nov 3.

2.

Pseudomonas aeruginosa causes acute lung injury via the catalytic activity of the patatin-like phospholipase domain of ExoU.

Pankhaniya RR, Tamura M, Allmond LR, Moriyama K, Ajayi T, Wiener-Kronish JP, Sawa T.

Crit Care Med. 2004 Nov;32(11):2293-9.

PMID:
15640644
3.

The mechanism of action of the Pseudomonas aeruginosa-encoded type III cytotoxin, ExoU.

Sato H, Frank DW, Hillard CJ, Feix JB, Pankhaniya RR, Moriyama K, Finck-Barban├žon V, Buchaklian A, Lei M, Long RM, Wiener-Kronish J, Sawa T.

EMBO J. 2003 Jun 16;22(12):2959-69.

5.

Selectivity of effects of vasoactive intestinal peptide on macrophages and lymphocytes in compartmental immune responses.

Goetzl EJ, Pankhaniya RR, Gaufo GO, Mu Y, Xia M, Sreedharan SP.

Ann N Y Acad Sci. 1998 May 1;840:540-50. Review.

PMID:
9629281
6.

Vasoactive intestinal peptide enhancement of antigen-induced differentiation of a cultured line of mouse thymocytes.

Pankhaniya R, Jabrane-Ferrat N, Gaufo GO, Sreedharan SP, Dazin P, Kaye J, Goetzl EJ.

FASEB J. 1998 Jan;12(1):119-27.

PMID:
9438417
7.

Supplemental Content

Loading ...
Support Center